<DOC>
	<DOCNO>NCT02247362</DOCNO>
	<brief_summary>One dose escalate strengths investigational influenza vaccine , VAX2012Q ( Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine ) , evaluate safety immunogenicity healthy adult 65 75 year age placebo-controlled study .</brief_summary>
	<brief_title>Study Safety Immunogenicity Quadrivalent Influenza Vaccine Healthy Adults Age 65-75 Years</brief_title>
	<detailed_description>The purpose study evaluate , stepwise fashion , dose level investigational quadrivalent influenza vaccine contain 2 influenza A strain 2 influenza B strain . This multi-center , randomize , double-blind , placebo-controlled , dose escalate study 200 healthy adult age 65-75 year administer single dose either placebo investigational influenza vaccine ( VAX2012Q , Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine ) one 3 dose level . Fifty 75 subject enrol dose level . Data safety immunogenicity collect dose level .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>Males female age 6575 year age time vaccination good health . Individuals stably treat hypertension may eligible . Able provide inform consent Willing receive unlicensed vaccine Willing provide multiple blood specimen Live community , independently assist living environment Based result Short Portable Mental Status Questionnaire rat normal great mild severity dementia As defined Canadian Study Health Aging Clinical Frailty Scale Class 1 5 Preceding administration study vaccine , receive receive 1 ) license investigational influenza vaccine product within 6 month , 2 ) investigational drug investigational vaccine product influenza vaccine within 30 day , 3 ) license live vaccine influenza vaccine within 4 week , 4 ) license inactivated vaccine influenza vaccine within 2 week Planned receipt Day 21 blood draw 1 ) license investigational influenza vaccine product , 2 ) investigational drug investigational vaccine product influenza vaccine , 3 ) license live vaccine influenza vaccine , 4 ) license inactivated vaccine influenza vaccine History excessive alcohol use , drug abuse significant psychiatric illness Has chronic illness medically stable , receive concomitant therapy medication dose stable least 3 week prior immunization condition could interfere subject 's participation study interpretation study result Clinically significant abnormal liver function test screen Subjects Grade 2 high abnormality total bilirubin screen Subjects follow laboratory abnormality screen : Creatinine &gt; 1.7mg/dL , Hemoglobin &lt; 11g/dL female ; &lt; 12.5 g/dL male , WBC &lt; 2500cell/mm3 &gt; 15,000cell/mm3 Platelet Count &lt; 125,000cell/mm3 Positive serology HBSAg , HCV HIV antibodies Having cancer receive treatment cancer within three year , exclude minor skin cancer , allow unless locate vaccination site . Persons history cancer diseasefree without treatment three year eligible . Persons impair immune responsiveness ( cause ) , include Type 1 diabetes mellitus auto immune disorder know suspected autoimmune disease Persons congenital immunodeficiency history acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede six month . Persons history severe allergic reaction previous vaccination hypersensitivity seasonal influenza vaccine component Persons history GuillainBarré Syndrome Receipt donation blood blood product 8 week prior vaccination three week study period follow vaccination Acute disease within 72 hour prior vaccination . An oral temperature &gt; 100.4°F ( 38°C ) Systolic blood pressure &lt; 85 mm Hg subject whose hypertension untreated unstable antihypertensive therapy systolic BP ≥ 160 mm Hg diastolic BP ≥ 100 mm Hg require medical intervention one drug intensive therapy previously use indicate . Body Mass Index &gt; 40 Disorders coagulation Women le 1 year post menopausal A clinical diagnosis influenza within previous 6 month Any condition circumstance , opinion Principal Investigator , pose unacceptable risk participation study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>